Eyepoint Pharmaceuticals Inc (EYPT) — Capital Reinvestment Ratio

Latest as of June 2023: 0.01x

Eyepoint Pharmaceuticals Inc (EYPT) has a Capital Reinvestment Ratio of 0.01x as of June 2023, meaning it reinvests 0% of its operating cash flow ($57.02 Million) in capital expenditures ($396.00K). See debt-free asset ratio of Eyepoint Pharmaceuticals Inc to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$57.02 Million
USD

Capital Expenditures

$396.00K
USD

Data as of

Jun 2023
Most recent filing

Eyepoint Pharmaceuticals Inc Capital Reinvestment Ratio (2010–2023)

This chart tracks Eyepoint Pharmaceuticals Inc's Capital Reinvestment Ratio across 3 annual periods. Check Eyepoint Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc (2010–2023)

Year-by-year Capital Reinvestment Ratio for Eyepoint Pharmaceuticals Inc from 2010 to 2023. For live market cap and broader valuation context, see Eyepoint Pharmaceuticals Inc (EYPT) market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 1.86x $1.88 Million $3.48 Million ▲ +11780.6%
2015 0.02x $10.30 Million $161.00K ▲ +931.8%
2010 0.00x $9.90 Million $15.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow